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Xenotransplantation: Risks, Clinical
Potential, and Future Prospects
The reemergence of xenotransplantation as a
therapeutic option for the hundreds of thousands
of people dying each year of heart, kidney, lung,
and liver failure has raised ethical, social, and
scientific questions. End-stage organ failure is one
of the most important public health problems fac-
ing Americans today. Heart failure, for example,
kills four times as many people as does HIV infec-
tion and three times as many people as does breast
cancer; it is a disease with an increasing incidence,
and the cost of taking care of affected patients is
8 to 35 billion dollars each year. The single most
effective therapy for it is transplantation. Preven-
tive therapies have had little impact on diseases
due to end-stage organ failure and are unlikely to
have an impact at least in the next decade. In the
meantime, demand for organs, which far outstrips
the supply, continues to grow. It has been esti-
mated that approximately 45,000 Americans un-
der age 65 could benefit each year from heart
transplantation, yet only 2,000 human hearts are
available annually. Patients are more likely to die
waiting for a human donor heart than in the first
2 years after transplantation.
Although clearly an experimental procedure,
xenotransplantation between closely related spe-
cies, such as baboons and humans, offers an alter-
native to allotransplantation as a source of human
organ replacement. Alternatives to allograft do-
nors, such as baboon or pig xenografts, require
serious investigation if clinical transplantation is
ever to meet the current demand and continue the
explosive growth pattern it has established over
the past quarter century.
Biologic cardiac replacement poses the immu-
nologic problems of rejection and infection associ-
ated with transplantation. Increasing clinical
experience worldwide has shown that rejection
and infection can be managed successfully in most
patients who receive human cardiac allografts.
Further, the introduction of cyclosporine as the
primary immunosuppressive agent for cardiac
transplant recipients has resulted in excellent
survival rates (85% 1-year survival at most cen-
ters) and has decreased illness associated with
infection and rejection. Although considerable ad-
vances have been made in the field of cardiac
xenotransplantation since its first clinical appli-
cation by Hardy in 1964 (1), it remains uncertain
whether xenotransplantation as destination ther-
apy can be successfully applied to humans. How-
ever, heart, kidney, and liver xenografts have been
able to support human life for an extended period.
It is this fact that investigators wish to exploit in
clinical bridging studies. By providing temporary
heart, kidney, or liver support as a bridge-to-
transplantation, these biological devices may al-
low patients to recover end-organ function and
await allograft transplantation in a more stable
clinical state, thus improving their chances of
survival. Bridging strategies cannot alleviate the
human organ donor shortage. However, if one
views bridging strategies as a first feasibility test,
then cross-species transplantation does offer the
possibility of eventual long-term organ replace-
ment. Success in this more ambitious goal would
help alleviate the human organ donor shortage.
Nonhuman primate organ donors have been
favored by those wishing to minimize the genetic
disparity between donors and human recipients.
Chimpanzees, although most compatible with
standard selection criteria (e.g., compatibility of
size and blood types), are unavailable as an ac-
ceptable source of clinical xenotransplantation.
Another choice is the baboon, which is not endan-
gered, has an anatomy and physiology similar to
those of humans, and grows to a weight of approxi-
mately 70 pounds. Baboon size would limit the
clinical application of xenotransplantation with
baboon organs to pediatric patients and small
adults. Small body size, the infrequency of blood
group O (universal donor) animals, and the lim-
ited number of colony-bred animals are distinct
disadvantages to the baboon as a donor.
Extended graft survival is possible, but ABO
blood group compatibility is mandatory before
xenotransplantation (2). The distribution of ABO
blood groups found in baboons indicates that ap-
proximately one third are group A, one-third
group B, and one-third group AB. Universal donor
group O, however, is exceedingly rare. In Ameri-
cans of Western European descent, the relative
frequency of blood types is approximately 45%
group A, 8% group B, 4% group AB, and 43% group
O (2).
Although available in large numbers, wild ba-
boons are not suitable from an infectious disease
perspective. Most experts have suggested that
colony-bred animals represent a more suitable
donor pool. However, these animals number only
in the hundreds and are, therefore, only likely to
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pediatric population with end-stage organ failure.
Xenotransplantation between baboons and hu-
mans raises the issue of xenozoonoses (3,4). The
organisms of greatest concern are the herpes-
viruses and retroviruses, which can be screened
for and eliminated from the donor pool. Others
include  Toxoplasma gondii, Mycobacterium tuber-
culosis, and encephalomyocarditis virus. Less
likely to be found in animals raised in captivity in
the United States are the filoviruses (Marburg
and Ebola), monkeypox, and Simian hemorrhagic
fever virus. Organisms that are unlikely to be
transmitted with an organ transplant (but should
be screened for) include lymphocytic choriomen-
ingitis virus, gastrointestinal parasites, and GI
bacterial pathogens.
The risk for xenozoonoses is likely to be re-
stricted to the xenogeneic tissue recipient. Never-
theless, one must consider and anticipate the
potential for xenozoonotic transmission through
the human population, constituting a public
health concern. The risk for recognized zoonotic
pathogens can be reduced, if not eliminated, by
controlling the donor animal vendor source and
the individual donor animal by employing de-
scribed screening tests and strict sterile proce-
dures during organ harvesting and donor autopsy
for tissue and blood. The risk for unrecognized
pathogens is present but ill defined.
Surveillance for the transmission of known or
unknown pathogens among health care workers
must be conducted by monitoring for unexpected
or unexplained adverse health events. It is diffi-
cult to monitor for the unknown; therefore, sur-
veillance should include notifying the principal
investigator’s office of any unexplained illness in
exposed health care workers, as well as telephone
interviews of these personnel every 6 months by
the principal investigator’s office.
Concurrent with scientific advances in
xenotransplantation have been the necessary
ethical debates concerning the appropriateness of
this endeavor (5). Disputes regarding animal ex-
perimentation notwithstanding, the ethical issues
raised by many of these debates are strikingly
similar to those put forth 25 years ago in reference
to the (then new) field of human heart transplan-
tation. Indeed, the timeless nature of these que-
ries itself attests to their essence, for such ethical
concerns are appropriate in the appraisal of any
new therapeutic procedure in medicine.
Can one ever hope to determine if or when the
clinical application of xenotransplantation is jus-
tified? The assessment of any experimental ther-
apy, as Fox and Swazey (6) have suggested, should
encourage the investigator to address three criti-
cal questions: 1) in the laboratory, what defines
“success” sufficient to warrant advancement to
the clinical arena? 2) under what clinical condi-
tions should this advancement proceed? and 3) in
the clinical arena, what defines “success” suffi-
cient to warrant further evaluation (6)? Providing
answers to this threefold inquiry requires a reli-
ance upon defined “success,” itself an appraisal of
judgment that can only confidently be made in
retrospect.
Because human heart transplantation is now
considered by most justifiable for the treatment of
end-stage heart disease, I would first like to re-
view the history of cardiac allotransplantation in
light of its ability to address the above threefold
inquiry. I will also discuss the history of cardiac
xenotransplantation with reference to scientific
advances made in the field throughout the past
quarter century. Finally, in light of these analyses,
I hope to illustrate the role of baboon heart
xenotransplantation as an alternative to allo-
transplantation for permanent cardiac replace-
ment in the treatment of end-stage heart disease.
After the first human cardiac allograft proce-
dure performed by Barnard in 1967 (7) the field of
cardiac transplantation witnessed a surge in both
enthusiasm and attempted trials, which was fol-
lowed by a marked drop in procedures throughout
the 1970s because of poor survival rates. During
the initial peak, 21 human heart allotransplants
were performed in the 6-month interval between
December 1967 and June 1968 (with a cumulative
1-year survival of  22%), and 105 cardiac allo-
transplantations were performed in 1968 alone
(8-10). However, these early clinical trials were
marred by numerous failures, as 65% of persons
undergoing the procedure before June 1970 died
within 3 months of transplantation (6).
Few centers continued animal research and
human procedures during the so-called black
years of cardiac transplantation. The initial explo-
sion in clinical trials accordingly elicited numer-
ous responses suggesting that too much was being
attempted too soon.
Some would propose that this was the price of
eventual “success,” and that further experimental
studies at the time could not have avoided early
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be, a tacit recognition by medical innovators that
the ultimate experiment must be performed in
humans, for no animal model can truly reflect the
human condition. Proponents of allotransplanta-
tion at the time of the first heart transplantation
cited the more than 60-year history of experimen-
tal cardiac transplantation, beginning with Car-
rel’s original work in 1905. Although most of this
work began in the 1930s, subsequent investiga-
tions regarding the experimental transplantation
of mammalian hearts showed that cardiac trans-
plantation was technically feasible and suggested
the possibility of clinically relevant survival rates.
During the decade before Barnard’s first clinical
application, cardiac allograft survival had been
shown to exceed 250 days (mean 103 days) in adult
dogs treated with an immunosuppressive regimen
that included azathioprine and methylprednisone
used intermittently. The mean survival in un-
treated dogs used as controls was 7 days (11). 
Since that time, with further expansion of
knowledge in virtually all areas of clinical cardiac
transplantation, 1-year survival has increased
from 67% in 1976, to approximately 85% reported
currently at most hospital centers (3). Human
recipients have survived for as long as 20 years
after transplantation, and the 10-year posttrans-
plant survival rate is now approximately 45% (12).
While these figures depict a clear improvement in
raw survival, cardiac transplantation is still not a
cure for end-stage heart disease. Recipients must
take immunosuppressive medication for life and
be monitored for infection, rejection, and graft
arteriopathy. However, these results are impres-
sive considering that the recipient population to-
day is considerably sicker than earlier allograft
candidates. In light of these findings, few would
deny cardiac allotransplantation its present claim
to “success.” To further understand the evolution
of this achievement, however, we may now look
back upon the early years of cardiac allotransplan-
tation and try to address the proposed threefold
inquiry.
First, for Barnard and co-workers what can we
presume as “success” warranting advancement to
the clinical arena? They performed the first hu-
man adult cardiac allotransplantation when the
maximum survival in immunosuppressed adult
dogs had been 250 days (average survival 103
days) (11) and suggested that “against the back-
ground of this research . . . the time arrived when
a cardiac transplant could be contemplated with
hope of success” (7). Indeed, in their report of this
case, they further described the scientific basis of
their clinical advancement by explaining that
“this achievement did not come as a surprise to
the medical world. Steady progress toward this
goal had been made by immunologists, biochem-
ists, surgeons, and specialists in other branches of
medical science all over the world during the past
decades to ensure that this, the ultimate in car-
diac surgery, would be a success” (7). Although we
may, in retrospect, consider them justified in their
declaration, in fact, at that time the endeavor was
highly controversial and came as a surprise to
much of the medical world.
Second, under what conditions did they proceed
with this clinical trial? Given the “hope of suc-
cess,” Barnard and colleagues selected a patient
“considered to have heart disease of such severity
that no method of therapy short of cardiac trans-
plantation could succeed” (7). The patient, a 54-
year-old man, had remained in intractable
congestive heart failure (following multiple myo-
cardial infarctions) despite all medical manage-
ment (13).
Finally, in this clinical arena, what defined for
Barnard and colleagues “success” warranting fur-
ther investigation? A concurrent editorial in the
South African Medical Journal may provide some
insight into their thinking: “The claim ‘successful’
can be used even at this early stage because to-
date it is a feat which makes medical history, no
matter how short the further survival of the pa-
tient might be (4). “Success,” by such an analysis,
was thus not targeted posttransplant survival
time, but rather any posttransplant survival time
(given the ground-breaking nature of the en-
deavor). Further editorials regarding the ethics of
cardiac transplantation viewed the procedure as
a legitimate experiment but not a treatment (15),
while in 1968, the American College of Cardiology
suggested (with regard to the “success” of allo-
transplantation) that results varied: “. . . the spec-
trum of success ranges from short-term
restoration of circulation to complete physical re-
covery” (16).
Indeed, “success” did vary along a spectrum of
results. Barnard and colleagues’ first allotrans-
plant recipient lived for 18 days and ultimately
died of pneumonia. However, their second recipi-
ent, 1 month later, survived more than 19 months
before dying of chronic rejection (17). Their third
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transplantation and ultimately died of carcinoma
of the stomach without signs of acute or chronic
rejection (18). One can only speculate how differ-
ent the world reception to allotransplantation
would have been had the latter two patients rep-
resented the first and second recipients of cardiac
allotransplants. Would these survival data be con-
sidered “success,” or would they still pale in com-
parison with the theoretical goal of obtaining a
graft that could function normally indefinitely?
Clinical cross-species transplantation dates to
the early twentieth century, with kidney
xenografts from rabbit, pig, goat, non-human pri-
mate and lamb donors (19). After these early fail-
ures, the scientific literature was largely devoid of
reports of clinical xenotransplantation for nearly
40 years. In 1963, Reemtsma and  colleagues
described six human recipients of chimpanzee kid-
neys, the longest survivor of whom died of causes
unrelated to rejection 9 months after xenotrans-
plantation (20).
The first cardiac xenotransplantation, per-
formed by Hardy in 1964, also represented the
first attempt at cardiac transplantation in hu-
mans, predating Barnard’s report by nearly 4
years (1). Since 1964, when Hardy and colleagues
at the University of Mississippi performed the
world’s first heart xenotransplant using a chim-
panzee as a donor, there have been eight docu-
mented attempts at clinical heart xeno-
transplantation. Five of these donors were non-
human primates (2 baboons, 3 chimpanzees) and
three were domesticated farm animals (1 sheep, 2
pigs) (21-25). The longest survivor was a newborn
infant with hypoplastic left heart syndrome.
“Baby Fae” was the recipient of an ABO-blood
group mismatched baboon heart that functioned
for 20 days (26). However, by the time the first
human neonatal cardiac xenotransplantation was
performed by Bailey in 1984 (the so-called “Baby
Fae” case), there had been only limited experi-
mental experience with prolonged graft survival
in the newborn xenotransplant recipient. Studies
presented by Bailey and co-workers shortly before
the Baby Fae case described a mean survival time
of 72 days in newborn lamb-to-goat xenotrans-
plants, with one survivor living to 165 days (27).
This advancement of xenotransplantation into
the clinical forum was met with resistance in the
medical community because of a perception that
research with acceptable survival “success” had
not been achieved experimentally. As Losman in
an editorial regarding the Baby Fae experience
stated, “It appears that this baboon-to-infant
transplantation did not rest on such a [scientific]
basis [as did Barnard’s earlier operation in 1967]
”(28).
During the past 3 years, investigators at the
University of Pittsburgh reported two cases in
which they transplanted a baboon liver into a
human recipient, obtaining a 70-day survival in
their first reported case, and a 26-day survival in
the second (29; J.J. Fung, pers. comm.) The inves-
tigators’ overwhelming effort to prevent rejection
led them to use a harsh immunosuppressive regi-
men that permitted multiple life-threatening
infections. Rejection was not the major clinical
obstacle they encountered; therefore, they recom-
mended a more directed and less arduous immu-
nosuppressive regimen for future patients.
More alarming have been the attempts to apply
xenotransplantation of distantly related species
to the clinical arena. In 1968, both Cooley and
Ross transplanted sheep and pig hearts, respec-
tively, into dying human recipients (30,31). Both
grafts failed upon reperfusion, presumably be-
cause of hyperacute rejection.
More recently, Czaplicki and co-workers in
1992 described a case in which they attempted the
xenotransplantation of a pig heart into a human
recipient with Marfan’s syndrome (32). By their
report, no evidence of hyperacute rejection was
present at the time of death nearly 24 hours after
xenotransplantation. Their protocol used an un-
usual immunosuppressive regimen in which both
donor and recipient received, in addition to con-
ventional immunosuppression, both thymic tissue
extracts and fetal calf sera. This regimen also
included the extracorporeal perfusion of two pig
hearts with the recipient’s blood in an attempt to
remove human anti-pig antibodies before the or-
thotopic transplantation of the functional pig
heart (33). As astonishing as this case may be in
its extension to the clinical arena of a technique
not yet shown to be effective in the experimental
laboratory, it is not unique. Also in 1992, Makowka
and colleagues transplanted a pig liver into a
26-year-old woman dying of acute liver failure
from autoimmune hepatitis (pers. comm.). De-
spite the fact that, at present, it appears unlikely
that sufficient “success” has been achieved in the
laboratory regarding xenotransplantation be-
tween distantly related species to warrant
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gators were able to obtain approval from their
hospital’s ethics committee and institutional re-
view board to proceed with the clinical trial. Most
experts in the field of xenotransplantation share
the opinion that pig-to-human organ transplanta-
tion remains at least 3 to 5 years from clinical
trials.
Considerable advances in the field of cardiac
xenotransplantation have subsequently emerged
worldwide since Hardy’s first clinical attempt in
1964, with a better understanding of the xenore-
jection process and a more sophisticated insight
into mechanisms for its control. Extended graft
survival has been achieved in a number of differ-
ent experimental models, including a greater than
tenfold graft survival in non-human primates
treated with conventional cyclosporine-based im-
munosuppression (34,35) a more than thirtyfold
increase in survival over controls described by
Celli and colleagues in a rodent model (36), and
survival beyond 1 year reported by Kawauchi and
colleagues in a non-human primate model (37).
These findings support the potential for achieving
clinically relevant graft survival in humans.
The question is whether we have reached a
stage in laboratory experimentation to justify fur-
ther attempts at advancing cardiac xenotrans-
plantation to the clinical arena. If we view the
current status of experimental accomplishments
in xenotransplantation with the same scrutiny as
that of allotransplantation at the time of Bar-
nard’s endeavor, we are left with similar conclu-
sions; first, comparable graft survival time has
been achieved in animal models of xenotransplan-
tation as was evident for allotransplantation be-
fore 1967. Second, with our current
understanding of cardiac allotransplantation has
also come a greater awareness of its limitations.
Thus, the conditions for the advancement of
xenotransplantation arguably could be fulfilled by
a patient with end-stage heart disease who is a
candidate for allotransplantation, but for whom a
donor cannot be identified in time. Finally, the
clinical “success” of xenotransplantation might
also be considered (as was the case for allotrans-
plantation) any graft survival, and the goal of
xenotransplantation to strive for extended graft
survival.
However, political and scientific sensibilities
today clearly differ from those of the 1960s, and so
the critical assessment of xenotransplantation
must be more rigorous than our previous discus-
sion. Indeed, the above comparison was put forth
largely to underscore the more humble origins of
the (now) successful therapy (allotransplantation)
to which xenotransplantation is currently com-
pared.
What then defines “success” in the laboratory
warranting advancement from the laboratory to
the operating room? Having demonstrated dra-
matic prolongation of cardiac xenograft survival
through experiments in rodent and non-human
primate models (27,34-37), which model most
closely approximates the human condition (and
thus which therapy will be most successful in
avoiding clinical rejection) remains to be estab-
lished. Therefore, it is reasonable to suggest both
that we have reached a formidable limitation for
precisely predicting the applicability of experi-
mental laboratory evidence and that answers may
only be sought from experiment in humans. This
concept was realized by the American Medical
Association with regard to allotransplantation, in
reference to which it released an official statement
acknowledging this notion in 1969 (38).
Concerns most commonly voiced with respect
to the clinical application of xenotransplantation,
however, pertain to a larger ethical controversy
regarding human experimentation. Reemtsma, in
a related comment concerning the Baby Fae case,
suggested the following: “There is a widespread
misperception that medical treatments and surgi-
cal procedures are easily classified as either ex-
perimental or accepted. In fact, all treatments
have an element of experimentation, and new
surgical procedures are based on extrapolations
from prior work. . . . When does a surgeon decide
to apply a new operation to a patient? . . . the
decision is based on balancing, on the one hand,
the experimental evidence suggesting that the
procedure may succeed, and, on the other, the
clinical urgency. . . (39).
Under what conditions will the clinical ad-
vancement of xenotransplantation proceed? For
those initial patients in whom clinical xenotrans-
plantation will first be applied, clinical urgency, in
the complete absence of other suitable alterna-
tives, undoubtedly will represent the motivating
factor to proceed. Who will comprise this initial
cohort? As Caplan has pointed out: “There would
appear to exist a pool of terminally ill persons,
both children and adults for whom no therapeutic
alternatives exist or are likely to exist in the near
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sible to allow research involving xenografting in
human subjects to proceed in those areas where
no reasonable alternative to therapy exists (40).
In this context, innumerable reservations have
been voiced regarding the ethics of proposing al-
ternative experimental therapies to such patients
for whom therapy has either failed or is non-exis-
tent. However, with regard to clinical experimen-
tation under these circumstances, one must also
recall (as Shimkin has suggested): “To do nothing,
or to prevent others from doing anything, is itself
a type of experiment, for the prevention of experi-
mentation is tantamount to the assumption of
responsibility for an experiment different from
the one proposed” (41).
What is the goal of the clinical application of
xenotransplantation? The need for donor organs
irrefutably outweighs the resources available, and
mechanical devices and xenotransplantation have
emerged as the two most promising alternatives
to allograft cardiac replacement. Mechanical left
ventricular assist devices (LVADs) have witnessed
relative success as “bridges” in carefully selected
patients with heart failure. (A “bridge” is a tempo-
rary method of life support designed to carry a
patient indefinitely until a human heart can be
found and transplanted. It is not a “destination”
therapy.)
Criteria for LVADs exclude patients with biven-
tricular failure, and (because of the relatively
large size of the device) patients with a total body
surface area less than 1.5 square meters (~120 lb).
Thus, many women and virtually all children are
not candidates for mechanical left ventricular as-
sistance. As has been the case for Food and Drug
Administration protocols using LVADs, proposed
investigations involving biologic assist devices
(xenografts), have sought to evaluate a short-term
alternative to allotransplantation in patients for
whom a donor heart is not immediately available,
and death is imminent. Only candidates who meet
criteria for heart transplantation, but do not meet
criteria for LVAD insertion, would be considered
for a heart xenobridge. Similar clinical scenarios
have been proposed for other solid organ trans-
plants. Since they were first introduced by Cooley
in 1969, temporary mechanical circulatory sup-
port devices have become critically useful tools in
the therapeutic armamentarium available to pa-
tients awaiting transplantation (42). Neverthe-
less, at present, the widespread application of
mechanical circulatory support is limited both by
patient selection criteria and by the temporary
nature of the device. For excluded patients, as well
as many adult male candidates. For excluded pa-
tients, cardiac xenotransplantation may be the
only reasonable alternative to cardiac allograft
replacement.
Investigations in clinical xenotransplantation
have been accused of using “the guise of [being a]
bridge-to-transplantation” to appear acceptable to
Institutional Research/Ethical Boards (5). How-
ever, the use of xenografts (or mechanical devices)
solely as bridges to allotransplantation will not
increase the donor pool, and, therefore, successful
permanent xenotransplantation must itself be
seen as the target for future clinical investiga-
tions. The goal of these studies is thus not to
engage, as Hastillo and Hess (5) would suggest, in
the “premature use of unproven procedures in
fellow humans,” but rather to impact positively on
the current shortage of human donor organs (6).
In 1996, the clinical picture is no less bleak and
the conclusions no less valid. The question that
remains is not how but rather when xenotrans-
plantation should advance to the clinical arena.
Most of the uncertainties surrounding its ad-
vancement will only be answered by its undertak-
ing.
In the foreseeable future, clinical xenotrans-
plantation may achieve its targeted goal of ex-
tended graft survival. As was the case during the
early years of allotransplantation, clinical
xenotransplantation must persevere under the
consideration of and often in spite of scrutiny by
its most demanding critics, for while “success has
a hundred fathers, failure is an orphan” (43).
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